Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hemodialysis III: Nursing Management

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

One-Compartment Model: IV Infusion

One-Compartment Model: IV Infusion

Intravenous (IV) infusion is often utilized when continuous and controlled drug delivery is necessary, such as during surgery or in the treatment of chronic diseases. This method offers numerous advantages, including immediate drug action, precise control over dosage, and bypassing the first-pass metabolism.
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

How to perform pharmacokinetic research of antimicrobial drugs in critically ill patients undergoing continuous renal replacement therapy: a scoping review of all relevant pharmacokinetic factors.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025

Same author

Epidemiology and prediction of non-targeted bacteria by the filmarray pneumonia plus panel in culture-positive ventilator-associated pneumonia: a retrospective multicentre analysis.

Annals of intensive care·2025

Same author

Sepsis associated acute kidney injury is common among Aboriginal and Torres Strait Islanders with septic shock and has poor outcomes: A nested cohort study.

Nephrology (Carlton, Vic.)·2024

Same author

Effects of dexmedetomidine on kidney and brain tissue microcirculation and histology in ovine cardiopulmonary bypass: a randomised controlled trial.

Anaesthesia·2023

Same author

Postoperative systemic inflammation after major abdominal surgery: patient-centred outcomes.

Anaesthesia·2023

Same author

A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery<sup></sup>.

Anaesthesia·2022

Search research articles

Related Experiment Video

Updated: May 7, 2026

The Combination of Mechanically Isolated Stromal Vascular Fraction and Fibrin Hydrogel: A Processing Protocol

The Combination of Mechanically Isolated Stromal Vascular Fraction and Fibrin Hydrogel: A Processing Protocol

Published on: November 17, 2023

Infusion of hydroxyethyl starch-containing fluids.

C Aubron¹, R Bellomo

¹Australian and New Zealand Intensive care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia - rinaldo.bellomo@austin.org.au.

Minerva Anestesiologica

|September 18, 2013

Summary

Hydroxyethylstarch (HES) fluid infusions, once common, were linked to increased kidney injury risk and mortality in critically ill patients. Regulatory agencies have since issued warnings and suspended HES marketing authorizations.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Experiment Videos

Last Updated: May 7, 2026

The Combination of Mechanically Isolated Stromal Vascular Fraction and Fibrin Hydrogel: A Processing Protocol

The Combination of Mechanically Isolated Stromal Vascular Fraction and Fibrin Hydrogel: A Processing Protocol

Published on: November 17, 2023

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Area of Science:

Critical Care Medicine
Pharmacology
Nephrology

Background:

Hydroxyethylstarch (HES) was a widely used colloidal fluid for volume resuscitation.
Concerns existed regarding HES accumulation in organs and its impact on blood coagulability.
Previous use was widespread despite unresolved safety questions.

Purpose of the Study:

To evaluate the safety and efficacy of HES in critically ill patients.
To investigate the association between HES administration and renal outcomes.
To assess the impact of HES on patient mortality.

Main Methods:

Two large multicenter, double-blind, controlled trials were conducted.
Studies included septic and heterogeneous Intensive Care Unit (ICU) patient populations.
Meta-analyses were performed to synthesize findings from multiple studies.

Main Results:

HES infusion was associated with an increased risk of renal replacement therapy.
One study demonstrated a significant increase in mortality with HES administration.
Subsequent meta-analyses corroborated these adverse findings.

Conclusions:

HES administration poses significant risks, including kidney injury and increased mortality.
Regulatory actions, including FDA warnings and EMA suspension, reflect the evidence.
The clinical use of HES has been largely curtailed due to safety concerns.